Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cogent

50.45
+1.052.13%
Post-market: 50.450.00000.00%16:32 EDT
Volume:425.95K
Turnover:21.40M
Market Cap:2.49B
PE:-12.61
High:50.48
Open:49.41
Low:49.41
Close:49.40
Loading ...

Major Investment Alert: Cogent Biosciences Stock Sees Multi-Million Dollar Purchase!

TIPRANKS
·
3 hours ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
11 Jul

Cogent Biosciences Is Maintained at Overweight by JP Morgan

Dow Jones
·
11 Jul

Cogent Biosciences 22.2M share Spot Secondary priced at $9.00

TIPRANKS
·
09 Jul

Cogent Biosciences Shares Fall After Public Offering News

Dow Jones
·
09 Jul

Press Release: Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Dow Jones
·
09 Jul

Cogent Biosciences Receives Buy Rating on Promising Trial Results and Market Potential

TIPRANKS
·
08 Jul

Cogent Biosciences Is Maintained at Outperform by Leerink Partners

Dow Jones
·
08 Jul

Cogent Biosciences Up Nearly 31%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk

Dow Jones
·
07 Jul

Cogent Biosciences price target raised to $18 from $16 at Leerink

TIPRANKS
·
07 Jul

Cogent Biosciences price target raised at Jefferies after ‘home run’ data

TIPRANKS
·
07 Jul

Jefferies Adjusts Price Target on Cogent Biosciences to $28 From $23, Maintains Buy Rating

MT Newswires Live
·
07 Jul

Cogent Biosciences trading halted, volatility trading pause

TIPRANKS
·
07 Jul

Cogent Biosciences Shares Rise After Mastocytosis Treatment Reaches Primary Endpoint in Recent Study

Dow Jones
·
07 Jul

Cogent Biosciences Announces Positive SUMMIT Trial Results

TIPRANKS
·
07 Jul

Cogent announces statistical significance across all endpoints from SUMMIT trial

TIPRANKS
·
07 Jul

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

GlobeNewswire
·
07 Jul

Cogent Communications Holdings Inc : Moffettnathanson Cuts Target Price to $90 From $102

THOMSON REUTERS
·
30 Jun

Promising Outlook for Cogent Biosciences: Buy Rating Amid Anticipated Data Release and Attractive Risk/Reward Opportunity

TIPRANKS
·
30 Jun

Citi adds ‘upside 30-day catalyst watch’ on Cogent Biosciences

TIPRANKS
·
30 Jun